Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.7%

5 terminated/withdrawn out of 22 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

32%

7 trials in Phase 3/4

Results Transparency

60%

9 of 15 completed trials have results

Key Signals

2 recruiting9 with results

Enrollment Performance

Analytics

N/A

11(52.4%)

Phase 4

4(19.0%)

Phase 3

3(14.3%)

Phase 2

2(9.5%)

Phase 1

1(4.8%)

21Total

N/A(11)

Phase 4(4)

Phase 3(3)

Phase 2(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT06157177Phase 4Recruiting

Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.

Role: lead

NCT06256575Not ApplicableRecruiting

Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

Role: lead

NCT06382662Phase 4Completed

Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition

Role: lead

NCT06348303Phase 4Completed

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

Role: lead

NCT05616962Not ApplicableCompleted

Vasculera in Participants With Lipedema

Role: lead

NCT04793711Not ApplicableTerminated

EpiCeram for Skin Protection in Healthcare Workers

Role: lead

NCT02361437Not ApplicableWithdrawn

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

Role: lead

NCT03179605Phase 2Terminated

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

Role: lead

NCT02749799Phase 4Completed

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Role: lead

NCT02070965Phase 2Completed

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Role: lead

NCT01967069Phase 3Completed

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Role: lead

NCT02527421Phase 3Terminated

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Role: lead

NCT01947491Phase 3Completed

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

Role: lead

NCT02936271Not ApplicableWithdrawn

Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting

Role: collaborator

NCT00790985Not ApplicableCompleted

Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee

Role: lead

NCT00928837Not ApplicableCompleted

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

Role: lead

NCT02683408Not ApplicableCompleted

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

Role: lead

NCT02582424Not ApplicableCompleted

Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.

Role: lead

NCT00303017Not ApplicableCompleted

Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

Role: lead

NCT00435292Not ApplicableCompleted

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

Role: lead